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Abstract
We have previously shown that an Epoxyeicosatrienoic Acid (EET) -agonist has pleiotropic effects and reverses
cardiomyopathy by decreasing inflammatory molecules and increasing antioxidant signaling. We hypothesized that
administration of an EET agonist would increase Peroxisome proliferator-activated receptor-gamma coactivator
(PGC-1α), which controls mitochondrial function and induction of HO-1 and negatively regulates the expression
of the proinflammatory adipokines CCN3/NOV in cardiac and pericardial tissues. This pathway would be expected
to further improve left ventricular (LV) systolic function as well as increase insulin receptor phosphorylation.
Measurement of the effect of an EET agonist on oxygen consumption, fractional shortening, blood glucose levels,
thermogenic and mitochondrial signaling proteins was performed. Control obese mice developed signs of metabolic
syndrome including insulin resistance, hypertension, inflammation, LV dysfunction, and increased NOV expression
in pericardial adipose tissue. EET agonist intervention decreased pericardial adipose tissue expression of NOV,
while normalized FS, increased PGC-1α, HO-1 levels, insulin receptor phosphorylation and improved mitochondrial
function, theses beneficial effect were reversed by deletion of PGC-1α. These studies demonstrate that an EET
agonist increases insulin receptor phosphorylation, mitochondrial and thermogenic gene expression, decreased
cardiac and pericardial tissue NOV levels, and ameliorates cardiomyopathy in an obese mouse model of the
metabolic syndrome.

Keywords: Inflammation; Oxidant stress; Cardiomyopathy; Metabolic
syndrome; Hypertension; Myocardial biology

Introduction
Heart failure continues to be a serious health crisis with a current
estimate of more than 37 million persons worldwide [1]. Of these,
the prevalence of diabetes mellitus is 24% in patients with chronic
heart failure and 40% in those hospitalized with debilitating heart
failure. Chronic obesity and diabetes are potent mediators of diabetic
cardiomyopathy [1,2]. A recently discovered adipokine, nephroblastoma
overexpressed CCN3 (NOV/CCN3), is a multifunctional protein of the
CCN family which is involved in many pathophysiological processes,
including inflammation, interstitial fibrosis and renal tissue damage
and repair [3]. NOV also modulates cell proliferation, cell adhesion
activities and the subsequent induction of proinflammatory cytokines
and chemokines in human cardio metabolic patients. Elevated NOV
is attributed to increased obesity, plasma triglycerides and C-reactive
protein [4]. Elevated NOV has also recently been associated with
obstructive sleep apnea [5], a clinical syndrome that is strongly
associated to obesity, insulin resistance and cardio-metabolic disease
[5,6]. Abolition of NOV was found to decrease fat mass, improve
glucose tolerance, insulin sensitivity, and to decrease proinflammatory
cytokines and chemokines in adipose tissues of obese mice [7].
Impairment of mitochondrial energetics, increased reactive
oxygen species (ROS) production and the resultant oxidative stress
induces hypertension [8,9], and are considered primary risk factors
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in the development of diabetic cardiomyopathy [10]. Mitochondria
play a major role in ROS generation and maintain an intricate balance
between fusion and fission events [10]. The formation of interconnected
mitochondrial networks via fusion allows for the replication and
distribution of mtDNA across the reticulum, and is mediated by
dynamin GTPases, mitofusin (Mfn1 and Mfn2 [10,11]. In contrast, the
fission-induced dispersion of mitochondrial networks is governed by
dynamin-related protein 1 (DRP1) and mitochondrial fission 1 (Fis1).
Obesity and ROS induction contributes to a reduction in HO-1
levels by either inherited or sedentary lifestyle-induced dyslipidemia,
a decline in respiratory capacity, OXPHOS machinery, and ATP
production [12-14], contributing to mitochondrial dysfunction and
reduced energy expenditure [15-17]. Moreover, oxidative mutations
of mitochondrial fusion and fission proteins disable the capability
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of mitochondrial dynamics to maintain mtDNA integrity, further
enhancing ROS-mediated oxidative stress [18,19].
A master regulator of mitochondrial biogenesis is peroxisome
proliferator-activated receptor gamma coactivator-1 alpha (PGC-1α),
which regulates respiratory chain complexes and ATP synthases [2022]. PGC-1α levels in cardiomyocytes are critical to mitochondrial
polarization, adequate output of ATP for cardiac energy supply, and
increases in VO2 [22,23]. As excessive adipose tissue accumulation
is a significant source of ROS and pro-inflammatory cytokines that
may ultimately result in LV diastolic dysfunction, increased fibrosis
and decreased contractility [14,24,25]. Ectopic fat accumulation
and inflammation adjacent to the epicardium and pericardium has
local deleterious effects on cardiac structure and function, further
contributing to cardiomyopathy [24,26-28]. We previously showed
that PGC-1α is regulated by EETs in adipocyte cells [29]. EETs are
generated by a family of cytochrome P450 (CYP) monooxygenases and
epoxygenases through their metabolism of arachidonic acid [30,31].
While ROS can rapidly hydrolyze EETs (reviewed in [14], EET agonists
prevent both vascular complications and adiposity, while expansion of
adipose tissue impairs the generation of EETs in vivo [32-35].
We hypothesize that the beneficial effect of EET-agonists on
cardiac function is mediated by a reduction in the local secretion of
inflammatory molecules such as NOV by pericardial fat, accompanied
by upregulation of PGC-1α and HO-1 and amelioration of obesitymediated cardiomyopathy. We further hypothesize that EET
upregulation may change the pericardial adipocyte phenotype from
white to beige-like adipocytes resulting in increased expression of
thermogenic genes and improved mitochondrial biogenesis and
function.

Age-matched C57BL/6J mice (C57) (Jackson Labs) were used as
WT (lean, C57) controls. All mice were fed regular (Harlan, Teklad Lab
Animal Diets, US). Mice (db/db) were treated as follows:

•

Control

•

Administered 2 bolus injections of 40-70 x 106 TU/mouse in
80-100 μl of Ln-non-target-shRNA (Dharmacon, Lafayette,
CO, US) into the retro orbital vein,

•

Injected intraperitoneally with the EET-agonist twice/week for
eight weeks at a dose of 15 mg/kg body weight,

•

EET-agonist and administered 2 bolus injections 40-70 x 106
TU/mouse in 80-100 μl PGC-1α (sh) lentivirus (Dharmacon)
into the retro orbital vein at 3 and 5 weeks after the start of
EET-agonist injections.

At the end of the study, mice were euthanized with ketamine
(100 mg/kg)/xylazine (10 mg/kg) administration followed by cervical
dislocation. Body weight and fat content were measured at sacrifice.
All animal studies have been approved by the appropriate ethics
committees of the NYMC, IACUC institutionally approved protocol in
accordance with the NIH guidelines.

Fasting blood glucose, glucose tolerance test and blood pressure
measurement
Fasting blood glucose measured following a 6 h fast. For the glucose
tolerance test, mice were injected intraperitoneally with glucose (2.0
g/kg body weight) after which blood glucose was measured every 30
minutes up to 120 min. Blood pressure measured using standard tailcuff method [36].

Materials and Methods

Echocardiogram measurement of fractional shortening

Cell culture

Echocardiography was performed using a 12-MHz probe on
isoflurane anesthetized mice. Images of the left ventricular (LV)
diameter was obtained in M-mode and used to measure the enddiastolic and end-systolic diameters from which the LV fractional
shortening was calculated [36].

Generation of PGC-1α-deficient cells using lentivirus: 3T3-L1
murine pre-adipocytes were purchased from ATCC (ATCC, Manassas,
VA). Cells were cultured in α-minimal essential medium (α-MEM,
Invitrogen, Carlsbad CA) supplemented with 10% fetal bovine serum
(FBS, Invitrogen, Carlsbad, CA) and 1% antibiotic/antimycotic
solution (Invitrogen, Carlsbad, CA). The cultures were maintained at
37°C in a 5% CO2 incubator and the medium was changed after 48 h
and every 3~4 days thereafter, as described previously [29]. SMART
vector lentiviral shRNA-PPARGC1A or scrambled RNA (Dharmacon,
Lafayette, CO) was applied to 3T3-L1 cells to establish a stably
transduced cell line, as described [29].

Animal protocols
We used db/db mice as a model of obesity induced diabetic
cardiomyopathy as these mice develop insulin resistance, hyperglycemia
and fail to control gluconeogenesis, leading to peripheral neuropathy
and myocardial disease. Sixteen week old male db/db mice, on
C57BL/6J background (Jackson Labs, Bar Harbor, ME), were divided
into four treatment groups, 6 mice per group, following a 16-week
acclimatization period weighing approximately 54 g at the start of the
experiment (data not shown):

•

Control

•

Ln-non-target-shRNA

•

EET-agonist

•

EET-agonist plus Ln-PGC-1α-shRNA
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Determination of oxygen consumption and respiratory
quotient
The Oxylet gas analyzer and air flow unit (Oxylet; Panlab-Bioseb,
Vitrolles, France) was used to determine individual mouse VO2 and
RQ as previously described [36].

ATP and mitochondrial copy number measurement
ATP content was quantified in heart tissue (10 mg/mouse) using
an ATP Colorimetric Assay Kit (ABCAM, Cambridge, MA) as per
the instructions provided by the manufacturer. Mouse Mitochondrial
DNA Copy Number Kit (Detroit R&D, Inc., Detroit, MI) was used to
measure mtDNA Copy Number.

Real-time qPCR and western blot analysis
For real-time PCR analysis total RNA was extracted from heart
and pericardial fat tissues with TRIzol® (Ambion, Austin, TX). A High
Capacity cDNA Reverse Transcription Kit (Applied Biosystems) was
used to synthesize cDNA from total RNA. Specific TaqMan® Gene
Expression Assay probes (Fisher Scientific, Waltham, MA) for mouse
PGC-1α, HO-1, NOV/CCN3, COX-1, PRDM16, CCL2, Adiponectin,
TNFα, IL-6 and GAPDH were used as previously described. For
Western blot, tissues were first lysed in RIPA buffer supplemented
with protease and phosphatase inhibitors (Complete™ Mini and
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PhosSTOP™, Roche Diagnostics, Indianapolis, IA) and total protein
content was analyzed by the Bradford method (BIO-RAD, Hercules,
CA). Immunoblotting was performed for select proteins [18,36].

Measurement of HO and EET levels
Heart tissue was lysed in RIPA lysis buffer, CO released and EET
levels were analyzed as previously described [18,36,37].

Statistical analysis
Data values are expressed as means ± S.E.M. Student’s t-test was
used for pairwise comparison and one-way ANOVA with Bonferroni’s
post-test for comparison was used to calculate the significance of
mean value differences using one-way analysis of variance. The null
hypothesis was rejected at p<0.05.

Results
EET-agonist administration increases endogenous EET levels
and improves metabolic function
Although the db/db mice treated with the EET agonist ate the
same amount of food as the other groups during treatment, they
weighed significantly less at the experimental endpoint 45.2 ± 1.33
g, than control mice (p<0.05) (63.9 ± 1.58 g). Knockdown of PGC1α reversed the beneficial effect of EET-agonist with mice weighing
54.9 ± 3.65 g at the experimental endpoint (Table 1). Fasting blood
glucose in the db/db control, and EET-agonist and EET-agonist
with PGC-1α (sh) treated mice was 355 ± 22.2 mg/dL, 134 ± 6.5
mg/dL, and 205 ± 5.5 mg/dL, respectively (Table 1). Knockdown of
PGC-1α reversed the effects of EET-agonist treatment. As seen in
Table 1, EET-A treatment of db/db mice improved (p<0.05) glucose
tolerance as compared to db/db control, an effect that was inhibited
in ln-PGC-1α (sh) db/db mice.
Blood pressure was reduced (p<0.05), oxygen consumption
increased (p<0.05), and the CO2/O2 ratio was decreased with EETagonist treatment (p<0.05) (Table 1). These EET-agonist-mediated
effects were significantly reduced in EET-agonist-treated mice
administered Ln-PGC-1α (sh). Obesity was associated with an increase
in heart weight as compared to mice treated with the EET-agonist alone
(0.16 ± 0.004 vs. 0.13 ± 0.001, respectively), while the EET-agonist in
combination with decreased levels of PGC-1α prevented the beneficial
effect of EET-agonist on heart weight (0.14 ± 0.006) (Table 1).

Importantly, EET-agonist is known to inhibit sEH, and therefore
may directly result in the observed elevation of endogenous cellular
levels of EET in cardiac tissues, an effect that was prevented in PGC1α-deficient mice treated with EET-agonist (Table 1).
Glucose tolerance was improved (p<0.05) in db/db mice treated
with EET-agonist with a decrease in fasting glucose, suggesting
increased insulin sensitivity (p<0.05) (Table 1). This was partially
prevented (p<0.05) in PGC-1α-deficient db/db mice (Table 1).

EET-agonist treatment restores cardiac function and associated
signaling pathways
Cardiac function, as measured by echocardiography and
calculation of fractional shortening (FS), was significantly impaired
(p<0.05) in control db/db mice as compared to lean WT (C57) (Figure
1A and B). Fractional shortening was improved (p<0.05) in db/db mice
treated with EET-agonist (p<0.05) (Figure 1A and B), an effect that was
partially prevented (p<0.05) in PGC-1α-deficient db/db mice (Figure
1A and B). Injection of db/db mice with saline and non-target lentiviral
vector (vehicle and vector controls) had no effect on FS as compared to
control db/db mice (Figure 1A and B).
Cardiac tissues from control db/db mice expressed lower levels
(p<0.05) of pAMPKα and pIR972 as compared to C57 (WT C57Bl6)
mice (Figure 1C-E). Decreased phosphorylation of AMPKα in db/db
mice was associated with a reduction in phosphorylation of the insulin
receptor (Figure 1E). HO-1 and PGC-1α protein levels in db/db mice
were lower (p<0.05) compared to C57 mice (Figure 1F-H). Decreased
levels of HO-1 and PGC-1α in db/db mice were associated with an
increase in Fis, indicative of increased mitochondrial fission (Figure
1I). As seen in Figure 1 treatment of db/db with saline and non-target
lentiviral vector (vehicle and vector controls) had no effect on any of
the protein levels as compared to control db/db mice.

EET-agonist administration causes reduction of NOV
expression
Basal levels of pericardial adipose tissue expression of NOV were
significantly higher than in visceral fat (p<0.05) (Figure 2A). Cardiac
tissues expressed the highest levels of NOV compared to kidney and
liver (p<0.05) (Figure 2B). EET-agonist administration decreased
NOV in cardiac and pericardial adipose tissues (Figure 2C and D).
Importantly, a reduction in PGC-1α reversed the ability of EET-agonist

Control

EET-A

EET-A+Ln-PGC1α(sh)

Body Weight (g)

63.9 ± 1.58

45.2 ± 1.33*

54.9 ± 3.65#
15.4 ± 0.91

Food Intake (g)

15.2 ± 0.30

14.9 ± 0.59

Fasting Blood Glucose (mg/dL)

355 ± 22.2

134 ± 6.5*

205 ± 5.5#

Heart Weight (g)

0.16 ± 0.004

0.13 ± 0.001*

0.14 ± 0.006

Blood Pressure (mmHg)

161.9 ± 4.19

110.3 ± 3.58*

137.9 ± 2.59#

VO2 (mL/Min)

25.31 ± 0.501

34.70 ± 7.35*

26.01 ± 13.01#

RQ (CO2 Eliminated/O2 Consumed)

0.81 ± 0.005

0.75 ± 0.007*

0.82 ± 0.017#

EET levels in Cardiac tissue (pg/μg of protein)

50.93 ± 9.58

83.33 ± 5.10

55.36 ± 2.15#

*

Glucose Tolerance Test: Mean ± SEM Blood Glucose levels (mg/dl)
Group

0

30

60

90

120

Control

355.5 ± 19.3

550.0 ± 8.8

600.0 ± 0.0

557.3 ± 13.2

541.8 ± 7.0
237.7 ± 27.6

EET-A

134.0 ± 6.1

316.0 ± 5.7

339.3 ± 10.6

276.0 ± 23.0

EET-A+Ln-PGC-1α (sh)

205.3 ± 5.2

388.3 ± 40.7

388.0 ± 5.7

372.3 ± 18.7

305.0 ± 4.0

Lean

115.0 ± 4.5

318.8 ± 34.6

247.8 ± 16.1

169.3 ± 14.7

135.3 ± 10.7

Table 1: Metabolic parameters in db/db mice (Table showing food intake, final body weight, fasting blood glucose as well as glucose tolerance test, heart weight, blood
pressure, and oxygen consumption as well as respiratory quotient, and endogenous EET levels in cardiac tissues of control, EET-agonist treated, and EET-agonist treated
PGC-1α-deficient db/db mice. Results are mean ± SE, n=6, *p<0.05 vs. db/db control, #p<0.05 vs. db/db mice treated with EET-agonist alone).
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3.46 mm
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B)
80

*
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#
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0
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E)
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pAMPKα
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pAMPKα/AMPKα

AMPKα

0.6

pIR972

0.4

β-actin

F)
HO-1

1

0

Fis1

C57

non-target
+ saline
db/db mice

C57

control

β-actin

*

*

0.5

0

PGC-1α

control non-target
+ saline
db/db mice

control non-target
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db/db mice

1
0.5
0

*
C57

*
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control

I)
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0.2

*

0.6

0.15

*

0.4

0.1
*

*
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0

0.8
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H)
PGC-1α/β-Actin
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*

*

0.2

C57

pIR972/β-Actin

C)

C57

non-target
+ saline
db/db mice

control

0.2
0

C57

control non-target
+ saline
db/db mice

Figure 1: EET-agonist treatment improves left ventricular dilation, fractional shortening, and glucose tolerance. (A) Sample M-mode short axis echocardiographic
images showing LV dilation and FS in wild-type (C57) and db/db control, db/db non-target and vehicle (saline) injected, db/db treated with EET-agonist, and PGC1α-deficient db/db mice treated with EET-agonist; (B) Graph depicting left ventricular fractional shortening in each cohort (n=6, **p<0.05 vs. C57, *p<0.05 vs. control
and #p<0.05 vs. EET-agonist). Results are mean ± SE, n=6, *p<0.05 vs. db/db control, #p<0.05 vs. db/db mice treated with EET-agonist. Representative blots; (C)
and densitometric analysis of (D) pAMPKα/AMPKα, and (E) pIR972, representative blots (F) and densitometric analysis of (G) HO-1, (H) PGC-1α, and (I) Fis1 in
WT (C57), db/db control and db/db non-target and vehicle (saline) injected mice. Results are mean ± SE, n=6, *p<0.05 vs. C57 mice.
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NOV/GAPDH
in heart

8

0

1.2

2

mRNA
NOV/GAPDH

mRNA
NOV/GAPDH

10

1

0.5
0

*
Con

EET-A
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Figure 2: Expression of NOV in different tissues of control db/db mice. (A) NOV mRNA expression in pericardial fat and visceral fat; (B) NOV mRNA expression
in heart, kidney and liver; (C) Effect of EET-agonist treatment on NOV mRNA expression levels in heart of individual mouse, Effect of EET-agonist treatment on
NOV mRNA expression in (D) Pericardial fat and (E) Visceral fat of db/db control mice, db/db treated with EET-agonist mice, and PGC-1α-deficient db/db mice
treated with EET-agonist. Results are mean ± SE, n=6, *p<0.05 vs. db/db control, #p<0.05 vs. db/db mice treated with EET-agonist.

to reduce NOV in both cardiac and pericardial adipose tissues (Figure
2C and D). A similar trend was observed in visceral adipose tissue
(Figure 2E).

PGC-1α knockdown prevented EET-agonist-mediated
increase in Sirt1, phosphorylation of AMPKα, and IR972 in
cardiac tissue
Figure 3A shows efficient lentivirus-mediated knockdown
of PGC-1α in 3T3-L1 derived adipocytes in vitro. EET-agonistmediated induction of PGC-1α, HO-1 expression and HO-activity,
was associated with a decrease in NOV expression (Figure 3B-F).
EET-agonist led to a 2-fold upregulation of PGC-1α in cardiac tissues
compared to control mice (Figure 3B and C). The EET- agonistmediated increase in PGC-1α levels was prevented in Ln-PGC-1α (sh)
mice (Figure 3B and C). HO-1 levels were increased in EET-agonist
treated mice compared to control mice (p<0.05) (Figure 3B and D).
Ln-PGC-1α (sh) in EET-treated mice prevented the EET-agonistmediated induction of HO-1 expression and reduced it to the level
of db/db control mice (Figure 3B and D). The effect of EET-agonist
and PGC-1α knockdown on HO-1 protein levels was paralleled by
measurement of HO-activity (Figure 3E). Importantly, NOV protein
levels were reduced (p<0.05) (Figure 3F) in cardiac tissue of EETagonist treated mice, an effect reversed in PGC-1α-deficient mice,
confirming the changes observed in mRNA levels (Figure 2). EETagonist treatment increased Sirt1 and phosphorylation of both
AMPKα (Thr172) and AKT (Ser473) levels (p<0.05) mediating
an increase in insulin receptor phosphorylation and prevented by
lentivirus-mediated silencing of PGC-1α (Figure 3G-K).
Cardiovasc Pharm Open Access journal
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Increased EET-levels in cardiac tissues improves mitochondrial
function and biogenesis
EET-agonist increased Mfn2 expression and decreased Fis1
(Figure 4A-C). The EET-agonist-mediated effect on Mfn2 and Fis1
was reversed in PGC-1α-deficient mice (Figure 4A-C). The levels of
DRP1 were not impacted by either EET-agonist or lentivirus-mediated
suppression of PGC-1α (Figure 4A and D). EET-agonist improved
both mitochondrial function and biogenesis in cardiac tissues of EETagonist treated mice as assessed by the increase in ATP generation and
mitochondrial copy number. In contrast, in cardiac tissues of PGC1α-deficient mice treated with EET-agonist both ATP generation and
mitochondria copy number were significantly (p<0.05) decreased
(Figure 4E and F). Furthermore, EET-agonist increased mRNA
expression levels of an antioxidant gene MnSOD2 in cardiac tissue of
mice, the beneficial effects of EET was abolished by lentivirus-mediated
suppression of PGC-1α (Figure 4G).

EET-agonist treatment reduces inflammatory cytokines levels
and cardiac remodeling (MMP2)
The cardiac expression of MMP-2 protein was reduced in EETagonist treated db/db mice compared to control db/db mice (p<0.05),
which was prevented by Ln-PGC-1α (sh) (Figure 5A and B). EETagonist-mediated decrease of MMP-2 may explain the prevention of
cardiac remodeling, an effect reversed by silencing of PGC-1α (Figure
5A-D). TNFα and IL-6 in cardiac tissues of EET-agonist treated db/db
mice were reduced compared to cardiac tissues of control db/db mice
(Figure 5A-D), a result similar to pericardial fat tissue.
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Figure 3: Effect of EET-agonist treatment on levels of PGC-1α, HO-1, NOV Sirt1, pAMPKα, total AMPKα, pAKT, total AKT and pIR972 in cardiac tissue of db/db
mice. (A) PGC-1α mRNA levels in control (WT) and lentivirus-mediated knockdown of PGC-1α in 3T3-L1-derived adipocytes. Representative western blots; (B)
and G) and densitometric analysis of (C) PGC-1α, (D) HO-1, (E) HO-activity as measured by CO generation, (F) NOV, (H) Sirt1, (I) pAMPKα/AMPKα, (J) pAKT/
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Results are mean ± SE, n=6, *p<0.05 vs. db/db control, #p<0.05 vs. db/db mice treated with EET-agonist.

EET-agonist administration increases thermogenic and
mitochondrial genes in pericardial adipose tissues
The effect of EET-agonist on cardiac tissue extended to
pericardial adipose tissue. This is evidenced by increased levels of
HO-1, PGC-1α, and PRDM16 (thermogenic genes), and increased
mitochondrial function (COX-I) in pericardial adipose tissue
(Figure 6A-D). EET-agonist treated db/db mice exhibited increased
PGC-1α mRNA levels compared to db/db control mice (p<0.05),
whereas PGC-1α mRNA expression in pericardial adipose tissue of
EET-agonist-PGC-1α (sh) db/db mice was, as expected, lower than
control db/db mice (p<0.05; Figure 6A). EET-agonist increased
HO-1 mRNA levels compared to control mice (p<0.05), that was
prevented in Ln-PGC-1α (sh) mice (Figure 6B). COX-I mRNA
levels increased in EET-agonist treated mice (p<0.05) compared to
Cardiovasc Pharm Open Access journal
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control mice, that was prevented in Ln-PGC-1α (sh) mice (Figure
6C). PRDM16 is a thermogenic gene responsible for the conversion
of white fat to brown fat. EET-agonist treated mice expressed higher
PRDM16 mRNA levels as compared to control mice (p<0.05), while
lentiviral-mediated suppression of PGC-1α reversed the effect of
EET-agonist treatment (Figure 6D). Similarly, there was an increase
in adiponectin levels and decrease in TNF-α, IL-6 and the monocyte
chemoattractant CCL2 (Figure 6E-H). Adiponectin mRNA levels
were upregulated in mice administered EET-agonist as compared
to control mice (p<0.05), an effect that was blocked in PGC1α-deficient mice (Figure 6E). EET-agonist treated db/db mice
exhibited a decrease in TNF-α, IL-6 and CCL2 mRNA expression
levels in pericardial adipose tissue as compared to control mice
(p<0.05), while lentivirus-mediated silencing of PGC-1α prevented
the EET-agonist-mediated effect (Figure 6 F-H).
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Discussion
This report demonstrates that an EET agonist increases PGC-1αHO-1, associated with increased insulin receptor phosphorylation,
a decrease in fasting blood glucose and a reduction in pericardial
fat deposition while decreases cardiac and pericardial fat NOV
expression. Pericardial adipose tissue is a metabolically active organ
that secretes several adipokines including NOV that may be linked to
LV dysfunction. EET mediated decrease in NOV and the concurrent
increase in PGC1a-HO-1 results in an increase in thermogenic genes
Cardiovasc Pharm Open Access journal
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and improved mitochondrial biogenesis and function. Importantly,
this suggests that EET-mediated decreases in local expression of NOV
in pericardial fat may have a direct effect on LV fractional shortening.
EET-agonist treatment produced an improvement in left
ventricular FS, an effect that was reversed in mice with reduced levels of
PGC-1α and increased levels of NOV. These results are in accordance
with previous observations that PGC-1α deficiency caused LV dilation
and poor cardiac contractility [38], insulin resistance and increased
circulating lipid levels [39]. Our results suggest a new function for
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EET that is associated with a decrease in NOV levels. Additionally, we
demonstrate that EET-mediated suppression of pericardial fat secretion
of NOV accompanied by increased expression of PGC-1α –HO-1
and adiponectin. Thus, there seems to be an opposing relationship
between NOV and adiponectin, both in terms of expression and effect
on adipocyte maturation and function. Increased NOV in obesity
may potentiate adipocyte inflammation and hyperplasia that in turn
further increases inflammatory adipokines. EET-mediated decrease of
NOV and increase in PGC-1α-HO-1 expression results in improved
metabolic parameters in db/db mice highlighting that NOV, PGC1α and HO-1 are inter-related and have a major relationship in the
development of cardiomyopathy. NOV regulates various inflammatory
molecules, which impair insulin signaling and promote insulin
resistance. Increased NOV levels are associated with obesity, fat
deposition and insulin resistance in human cardio metabolic patients
[4]. Our results are supported by the observation that low levels of NOV
are associated with increased PGC-1α expression, decreased fat mass,
increased insulin sensitivity and decreased inflammation in adipose
tissue of mice fed a HFD [7]. However, the reciprocal relationship
between PGC-1α and NOV in pericardial fat and the high levels of
NOV in pericardial adipose tissue compared to the heart, suggest that
the regulation of NOV in pericardial adipose tissue is different from
that in cardiac tissue.
We demonstrate that EET mediated increases in PGC-1α results
in an increase in Mfn2, cytochrome C oxidase and ATP levels, which
identify PGC-1α as a major regulator of mitochondrial function
[18,36]. Since HO-1 enhances mitochondrial integrity and function
and EET-agonist treated mice deficient in PGC-1α display diminished
levels of HO-1, reduced levels of Mfn2, ATP, COX-I, and increased
levels of Fis1 make it is likely that EET mediates signaling through
the PGC-1α and HO-1 pathway. This also confirms that PGC-1α is
upstream of HO-1, and is therefore primarily responsible for the HO-1
mediated decrease of pro-oxidants including excess heme seen in vitro
and in animal models of obesity [34,35]. Heme abatement results in
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decreased levels of ROS and oxidative stress, both known causes of
mitochondrial fragmentation and cardiomyopathy [12,40]. Reduction
of HO-1 expression increases heme-mediated ROS levels, resulting in
an increase in inflammation [40,41]. HO-1 deficiency causes organ
damage in humans and mice [42]. Importantly, gene polymorphisms
that negatively regulate the global as well as monocyte-specific HO-1
expression has been shown to be associated with the risk of CVD and
atherosclerosis [43,44]. Further, ablation of HO-1 in adipose-specific
HO-1 knockout increases ROS through inhibition of mitochondrial
fusion and PGC-1α [18]. HO-1 degrades heme to ferrous iron,
biliverdin and CO and recent studies indicate that increased HO
activity, bilirubin and CO production reduces oxidative stress, and
pathological remodeling of the heart [25,45]. HO-1 and CO provides
cardioprotection [46], reduces infarct size [47], and protects human
stem cells against cell death [48]. The protective effects of increased
HO activity also prevent mitochondrial DNA depletion and improved
mitochondrial quality control [34,40]. HO-activity plays an important
role in mitochondrial electron transport, biogenesis and viability
[12,49]. The observation that EET-agonist increases mitochondrial
fusion and decreases mitochondrial fission supports the contention
that HO activity is mediated by PGC-1α, and is consistent with prior
observations that increased HO-1 levels, as well as CO-releasing
molecules, exert cardio-protective, anti-fibrotic, and anti-apoptotic
effects in both ischemic and non-ischemic cardiomyopathy [46,50].
A relationship between pericardial fat and cardiac contractility is
supported by the observation that EET-agonist reduced pericardial
adipose tissue deposition, NOV, and TNF-α, IL-6 and CCL2 levels.
EETs possess the ability to reprogram pericardial fat, altering phenotype
from inflammatory white to healthy functional beige adipocytes with
increased adiponectin levels and normal mitochondrial function
that express thermogenic genes. These include PRDM16, responsible
for the attenuation of cardiac remodeling and cardiomyopathy and
associated with increased energy expenditure in, and browning of,
adipose tissue, leading to synthesis of adipokines and obesity [51].
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db/db mice. mRNA levels of (A) PGC-1α, (B) HO-1, (C) COX-I, (D) PRDM16, (E) Adiponectin, (F) TNF-α, (G) IL-6, and (H) CCL2. Results are mean ± SE, n=6,
*
p<0.05 vs. db/db control, #p<0.05 vs. db/db mice treated with EET-agonist.

Ectopic fat accumulation within and around the heart increases
risk of cardiomyopathy associated with mitochondrial dysfunction,
highlighting the complex relationship between obesity, insulin
resistance and cardiac LV abnormalities [24,26-28,52]. Pericardial
and epicardial adipose tissues are a major source of adipokines,
inflammatory cytokines and ROS, which can contribute to cardiac
remodeling [53].
EET-induced PGC-1α activation reduced the levels of MMP-2 in
Cardiovasc Pharm Open Access journal
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cardiac tissue, providing mechanistic support for prior observations
that EET decreases cardiac fibrosis [25]. EET-related decrease in MMP2 and improvement in FS is accompanied by activation of AKT and
AMPK in cardiac tissue. Likewise, in metabolic organs such as the liver,
adipose tissue, and skeletal muscle, activation of AMPK stimulates
catabolic and inhibit anabolic processes [54]. EET-agonists offer a
unique multifactorial clinical approach to prevention and treatment
of diabetic cardiomyopathy and concomitant metabolic derangements
(Figure 7).
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Figure 7: Schematic description of the EET mediated NOV-PGC-1α-HO-1 in
mitochondrial biogenesis and function, and thermogenic genes PRDM16. EETmediated change of pericardial fat phenotype and increase in to expression of
mitochondrial signaling protein, thermogenic genes similar to that described to
beige type like adipose tissue. The EET-agonist-mediated reduction in NOV
subsequently increases PGC-1α and HO-1 leads to increased ATP production,
oxygen consumption, increased mitochondrial fusion, DNA copy number,
insulin sensitivity that all in concert leads to an improvement in cardiac function.
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The clinical ramifications of this pathway are substantial, given
its ability to reduce body fat mass, restore glucose homeostasis,
inhibit the generation of ROS, reduce adipose tissue inflammation,
enhance mitochondrial function and most importantly, restore
myocardial function. This study demonstrates for the first time that
EET upregulation of PGC-1α inhibits NOV, and prevents increased
expression of inflammatory markers through upregulation HO-1
in both the heart and pericardial adipose tissue, thwarting the
development of cardiomyopathy. Hence, the EET-agonist-mediated
reduction of NOV identifies it as a novel pharmacologic target to treat
myocardial dysfunction caused by obesity and diabetes mellitus.
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